Neoplasms Clinical Trials

A listing of 60 Neoplasms clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Neoplasms

1 - 12 of 60

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 60 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Neoplasms participants are California, Texas, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

NCT03366116

Recruiting

Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

07/03/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Solid Tumors

Learn More ›

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NCT01443468

Recruiting

Background: - Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a TP53 mutation. Researchers want to study other possible genetic causes of LFS, and factors that may increase or decrease cancer risk in people with the syndrome. Objectives: * To learn more about the types of cancers that occur in individuals with LFS. * To study the role of the TP53 gene in the development of cancer. * To look for other possible genes that cause LFS * To study the effect of LFS diagnosis on families. * To determine if environmental factors or other genes can change a person s cancer risk associated with LFS. Eligibility: * Individuals with a family or personal medical history of cancers consistent with LFS. * Individuals with a family or personal medical history of cancers that does not meet the diagnosis of LFS, but the history is suggestive for LFS (meets the diagnosis for the so-called Li-Fraumeni like syndrome) * Individuals with certain rare cancers * Individuals with a family or personal history of a TP53 gene mutation, with or without related cancer(s). Design: * Participants will fill out a medical history questionnaire and a family history questionnaire. * Blood samples will be collected for DNA and for storage. Cheek cell samples may be collected if blood cannot be obtained for DNA. Participants can choose to have or not have cancer screening with blood tests, imaging studies, and other exams. * Participants will complete questionnaires about their worries about cancer, stress levels, and coping strategies. Diet and physical activity questionnaires will also be given. Other psychological tests may be given as needed. * Participants will be monitored for several years, with regular followup visits to the National Institutes of Health, if indicated. Any changes in health or cancer status will be recorded. Read Less

Gender:

ALL

Ages:

All

Trial Updated:

07/03/2025

Locations: National Cancer Institute - Shady Grove, Bethesda, Maryland +1 locations

Conditions: Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations

Learn More ›

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

Recruiting

Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person s own immune cells (T cells); the T cells are genetically modified to target and kill tumor cells with high levels of MSLN. Objective: To test a new treatment (TNh... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

07/02/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms

Learn More ›

Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue

NCT06482515

Recruiting

Cancer-related fatigue affects at least 30-90% of patients with cancer, depending on the type of cancer and their treatment(s) (e.g., chemotherapy, radiation). It is not relieved by sleep or rest, and it sometimes can persist for years after a person's cancer was treated. The fatigue can be so bad that people cannot return to work, hobbies, family roles, or other daily activities, thereby greatly reducing quality of life. The causes of this fatigue are unknown, and we currently do not have anything that can reliably prevent or cure the fatigue. However, there are recent data suggesting that circadian rhythm, or a person's internal body clock, may be disrupted by the cancer experience and contribute to fatigue. Food intake is an external cue that can entrain circadian rhythm. We recently showed that cancer survivors are willing and able to eat all their food within a 10-hour eating window-a practice called time-restricted eating. Herein, we are testing time-restricted eating against a control group (matched for time-, attention, and expectancy) to see if time-restricted eating can indeed alleviate cancer-related fatigue. All participants will be asked to use the myCircadianClock smartphone app to log their food intake and weekly body weight measurements. The participants assigned to the time-restricted eating group will be asked to eat all their food in a 10-hour window during the day. People can choose their start time based on their schedule and preferences, but we ask that the window is the same for the whole study (e.g., 7am-5pm,9:30am-7:30pm). Black coffee and unsweetened tea are allowed before the eating window, and water and medicines are allowed at all times. The participants in the control group will meet with a nutritionist to discuss the American Cancer Society nutrition guidelines in cancer survivorship; they will not be restricted to when they can eat. Participants in both groups will give us valuable information regarding how diet is related to the experience of fatigue. The purpose of this study is to test the effects of a 12-week TRE intervention vs. an unrestricted eating pattern on fatigue, the sustainability of the program at 24 weeks, and the effects of TRE on circadian rhythm and sugar metabolism. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/02/2025

Locations: University of Maryland, Baltimore, Baltimore, Maryland

Conditions: Neoplasms, Blood Cancer, Fatigue, Diet Habit, Survivorship, Fasting, Intermittent

Learn More ›

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

NCT06884618

Recruiting

This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/02/2025

Locations: South Texas Accelerated Research Therapeutics (START), San Antonio, Texas +4 locations

Conditions: Neoplasms

Learn More ›

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

NCT02211755

Recruiting

Background: - Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers. Objectives: - To test the safety and efficacy of the drug combination of bortezomib and clofarabine. Eligibility: - Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy. Design: * Participants will be screened... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

07/01/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Myelodysplastic Syndromes, Lymphomas

Learn More ›

Sample Collection and Tracking for the Developmental Therapeutics Clinic

NCT03269578

Recruiting

Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. Researchers want to access people s medical records. This will allow them to link the research data from all their studies they have or will take part in. Researchers also want to collect medical data... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

06/28/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Lymphoma

Learn More ›

Collection of Tissue Samples for Cancer Research

NCT00900198

Recruiting

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. * To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites. Design: * This is a multicenter tissue procurement protocol with NCI as the coordinating center. * For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. * For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. * Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. * This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models. * Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first. Read Less

Gender:

ALL

Ages:

2 months and above

Trial Updated:

06/27/2025

Locations: UC Davis, Sacramento, California +16 locations

Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT00071045

Recruiting

This study will collect biological samples for use in research experiments aimed at better understanding the clinical features of certain diseases. The specimens may be used to evaluate the effectiveness of known therapies, refine treatment approaches, identify potential new therapies, and explore opportunities for disease prevention. The following individuals 2 years of age or older may be eligible for this study: * Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder who are being screened for or who are enrolled in a treatment study at the NIH Clinical Center * HLA-compatible donor family members (18 years of age or older) of the above patients who are being evaluated for or are enrolled in an NIH study as a stem cell transplant donor * Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder or a bone marrow failure condition who cannot participate in an NIH treatment protocol or travel to the NIH Clinical Center and who are referred for participation through their home health care provider. Research samples will be collected from participants when blood is drawn or bone marrow, urine, or stool is collected, or tumor or other tissue is biopsied as part of their general medical care. Investigators may periodically request an additional sample of blood, stool, or urine. Participants who are 18 years of age or older may donate a large number of white blood cells through a procedure called leukapheresis. This procedure is not part of general medical care and would be done for research purposes only. For apheresis, a catheter (plastic tube) is placed in a vein in the subject's arm. Blood flows from the vein into a cell separator machine, where the white cells are separated from the red cells, platelets, and plasma by a spinning process. The white cells are removed and collected, and the rest of the blood is returned to the subject through a second tube placed in the other arm. ... Read Less

Gender:

ALL

Ages:

Between 2 years and 100 years

Trial Updated:

06/26/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Hematologic Neoplasms, Healthy Volunteers

Learn More ›

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

NCT04449549

Recruiting

Background: People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs together can make rare cancers shrink or stop growing. Objective: To learn if nilotinib and paclitaxel will benefit people with rare cancers. Eligibility: People age 18 and older who... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

06/25/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms

Learn More ›

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796

Recruiting

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Gender:

ALL

Ages:

All

Trial Updated:

06/24/2025

Locations: University of Alabama Birmingham, Birmingham, Alabama +181 locations

University of Alabama Birmingham, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic Phoenix, Phoenix, Arizona

Arizona Cancer Center, Scottsdale, Arizona

Local Institution - 01021, Tucson, Arizona

City Of Hope, Duarte, California

University Of California San Diego Moores Cancer Center, La Jolla, California

Local Institution - 01206, Los Angeles, California

Local Institution - 01043, Sacramento, California

University of California, San Francisco- California, San Francisco, California

UCLA Medical Centre-Santa Monica, Santa Monica, California

Stanford Cancer Center, Stanford, California

University Of Colorado Cancer Center, Aurora, Colorado

Colorado Blood Cancer Institute, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

Local Institution - 01050, Washington, District of Columbia

The Mayo Clinic - Jacksonville, Davis-E, Jacksonville, Florida

Baptist Cancer Center, Miami, Florida

Local Institution - 01035, Orlando, Florida

H. Lee Moffitt Cancer Center and Research Institute University of South Florida, Tampa, Florida

Winship Cancer Institute of Emory University, Atlanta, Georgia

Northside Hospital, Inc, Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

University Of Chicago Medical Center, Chicago, Illinois

Local Institution - 01040, Maywood, Illinois

Local Institution - 01063, Niles, Illinois

IN Univ Simon Cancer Center, Indianapolis, Indiana

Local Institution - 01020, Indianapolis, Indiana

Kansas University Medical Center, Westwood, Kansas

Cancer Center of Kansas, Wichita, Kansas

University Of Kentucky, Lexington, Kentucky

Norton Cancer Institute Louisville Oncology, Louisville, Kentucky

Local Institution - 01026, New Orleans, Louisiana

University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Sidney Kimmel Comp Cancer Center at Johns Hopkins, Baltimore, Maryland

National Cancer Institute, Bethesda, Maryland

Local Institution - 01107, Boston, Massachusetts

Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts

Local Institution - 01106, Boston, Massachusetts

University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Karmanos Cancer Center Wayne State University, Detroit, Michigan

Providence Cancer Institute, Southfield, Michigan

M Health Fairview University of Minnesota Medical Center - East Bank, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Siteman Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 01030, East Brunswick, New Jersey

Hackensack University Medical Center, Hackensack, New Jersey

Morristown Memorial Hosp, Morristown, New Jersey

Local Institution - 01053, New Brunswick, New Jersey

New York Oncology Hematology P.C., Albany, New York

Roswell Park Cancer Institute, Buffalo, New York

Local Institution - 01066, New York, New York

Weill Cornell Medicine / New York Presbyterian Hospital, New York, New York

Icahn School Of Medicine At Mount Sinai, New York, New York

Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Local Institution - 01051, Rochester, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Novant Health, Salisbury, North Carolina

Oncology Hematology Care, Inc., Cincinnati, Ohio

University Hospitals of Cleveland, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Local Institution - 01074, Columbus, Ohio

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma

Willamette Valley Cancer Institute, Eugene, Oregon

Providence Portland Medical Center, Portland, Oregon

Oregon Health and Science University OHSU, Portland, Oregon

Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia, Pennsylvania

University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

UPMC Cancer Pavillion, Pittsburgh, Pennsylvania

Hematology and Oncology Associates of SC, LLC, Greenville, South Carolina

Local Institution - 01064, Sioux Falls, South Dakota

Sarah Cannon Research Inst, Nashville, Tennessee

Texas Oncology, Dallas, Texas

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

University of Texas- MD Anderson, Houston, Texas

Sam Clinical Research Center, San Antonio, Texas

Local Institution - 01033, Temple, Texas

Texas Oncology, P.A. - Tyler, Tyler, Texas

University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah

Intermountain Healthcare - LDS Hospital, Salt Lake City, Utah

University Of Virginia Health System, Charlottesville, Virginia

Local Institution - 01045, Norfolk, Virginia

Local Institution - 01023, Richmond, Virginia

Swedish Cancer Institute, Seattle, Washington

Local Institution - 01060, Seattle, Washington

Fred Hutchinson Cancer Center, Seattle, Washington

Local Institution - 01055, Tacoma, Washington

University Of Wisconsin, Madison, Wisconsin

Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin

Local Institution - 01069, Wauwatosa, Wisconsin

Peter MacCallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Not set

Jules Bordet Institut, Anderlecht, Not set

Universitair Ziekenhuis Brussel, Brussel, Not set

Local Institution - 05200, Gent, Not set

Uz Gent, Gent, Not set

University Hospital Leuven, Leuven, Not set

Local Institution - UNK 2, Leuven, Not set

University Of Calgary, Calgary, Alberta

Local Institution - 02802, Vancouver, British Columbia

Local Institution - 02801, Hamilton, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

CIUSSS de l'Est-de-l'Ile-de-Montreal, Montreal, Quebec

Helsinki University Central Hospital (HUCH), Helsinki, Not set

Hopital Henri Mondor, Creteil-Paris, Not set

CHRU de Lille France, Lille Cedex, Not set

Local Institution - 09601, Lyon, Not set

Local Institution - 09400, Marseille Cedex 9, Not set

Local Institution - 09602, Marseille Cedex 9, Not set

CHU Montpellier - Hôpital Saint Eloi, Montpellier CEDEX 5, Not set

Chu Hotel Dieu, Nantes Cedex 01, Not set

Hopital Saint Louis, Paris, Not set

Hospital Saint Louis, Paris, Not set

Local Institution - 09600, Paris, Not set

Centre Hospitalier Universitaire (CHU) de Bordeaux - Hopital Haut-Leveque, Pessac, Not set

Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, Not set

CHU La Miletrie, Poitiers Cedex, Not set

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse CEDEX 9, Not set

Gustave Roussy, Villejuif, Not set

Robert-Rossle-Klinik im HELIOS Klinikum Berlin-Buch Klinik fur Hamatologie, Onkologie u. Tumorimmuno, Berlin, Not set

Local Institution - 03155, Berlin, Not set

Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Not set

Local Institution - 03513, Dusseldorf, Not set

Local Institution - 03500, Frankfurt, Not set

Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Kinikum der Universitaeat zu Koeln, Koeln, Not set

Local Institution - 03454, Muenster, Not set

LMU Klinikum der Universität, München, Not set

Local Institution - 03503, Tuebingen, Not set

University Hospital of Ulm, Ulm, Not set

Universitatsklinikum Wurzburg Medizinische Klinik und Poliklinik II, Würzburg, Not set

Ospedali Riuniti di Ancona, Ancona, Not set

Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set

Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Not set

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Naples, Not set

Local Institution - 07500, Roma, Not set

Ospedale Pediatrico Bambino Gesu, Rome, Not set

Istituto Clinico Humanitas, Rozzano (MI), Not set

Local Institution - 07610, Torino, Not set

Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette, Turin, Not set

Hokkaido University Hospital, Sapporo-shi, Hokkaido

National Cancer Center Hospital, Chuo-ku, Tokyo

Toranomon Hospital, Minato-ku, Tokyo

Local Institution - 13202, Bunkyo-ku, Not set

Kyushu University Hospital, Fukuoka, Not set

Tokai University Hospital, Isehara City, Kanagawa, Not set

Nagoya City University Hospital, Nagoya, Not set

Osaka Metropolitan university Hospital, Osaka, Not set

Japan Red Cross Medical Center, Shibuya-ku, Not set

Jichi Medical University Hospital, Shimotsuke, Not set

Local Institution - 13804, Shinjuku City, Not set

Local Institution - 04650, Amsterdam, Not set

Erasmus Medical Center - Daniel den Hoed, Rotterdam, Not set

Local Institution - 04400, Utrecht, Not set

Oslo Universitetssykehus, Oslo, Not set

Institutul Clinic Fundeni, Bucuresti, Not set

Hospital Universitario Vall D hebron, Barcelona, Not set

Hospital Universitari Germans Trias i Pujol ICO Badalona, Barcelona, Not set

Institut Clinic de Nefrologia i Urologia - Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital San Joan de Deu Barcelona, Esplugues de Llobregat, Not set

Hospital Infantil Universitario Nino Jesus, Madrid, Not set

Hospital 12 De Octubre, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Virgen Del Rocio, Sevilla, Not set

Karolinska University Hospital Huddinge, Stockholm, Not set

Inselspital Bern, Bern, Not set

Local Institution - 10850, Leeds, Not set

Kings College Hospital, London, Not set

UCL Cancer Institute, London, Not set

Christie Hospital Nhs Trust, Manchester Withington, Not set

Somers Cancer Research Building, Shirley Southampton, Not set

Conditions: Neoplasms

Learn More ›

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933

Recruiting

This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric high-grade gliomas

Gender:

ALL

Ages:

Between 3 years and 21 years

Trial Updated:

06/23/2025

Locations: Holly Lindsay MD, Aurora, Colorado +4 locations

Conditions: Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma

Learn More ›

1 - 12 of 60